Company intelligence / Profile preview
Full-Life Technologies
Shanghai, Shanghai, Chinafull-life.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead candidate, ^225Ac-FL‑020 targeting PSMA in mCRPC, was progressing toward Phase I clinical trials as of early 2024. The company has raised over $110 million since its founding and aims to become a fully integrated radiopharmaceutical developer with end-to-end capabilities from R&D through manufacturing and commercialization. No published clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Radionuclide Drug Conjugates (RDC)Radiotherapeutics (radioisotope-labeled peptides, small molecules, single domain antibodies)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Major supply-chain partners for radioisotopes/logistics mentioned but not named specifically.
Beyond the preview
Go deeper on Full-Life Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Full-Life Technologies.